COREE’s HKEX IPO Application Lapsed, China’s Largest Paediatric Pharmaceutical Marketing & Promotion Service Provider

NewTimeSpace · 2026/06/18 09:42 · By Zehong Cheng

NewTimeSpace News: The listing application submitted by COREE Company Limited to the Hong Kong Stock Exchange on 18 December 2025 has lapsed upon the expiry of the six-month validity period, with China International Capital Corporation acting as the original sole sponsor. Originated from South Korea, the Company is an integrated healthcare solution provider with core operations in China and expanding global footprint. According to Frost & Sullivan, measured by 2024 revenue, it ranks as China’s largest service provider for paediatric pharmaceutical marketing, promotion and sales, capturing approximately 15.9% of the domestic market share.

NewTimeSpace News: The Main Board listing application filed by COREE Company Limited with the Hong Kong Stock Exchange on 18 December 2025 has now lapsed after the six-month statutory validity window expired, with CICC serving as the original sole sponsor.

Originating from South Korea, the Company is an integrated healthcare solution vendor whose primary business operations are based in China, while it continues to expand its international business layout. Committed to upgrading pharmaceutical supply chains via digital solutions, it fosters innovative development in biological healthcare and multi-functional nutrition sectors. During the track record period, the Group’s core businesses cover pharmaceutical marketing, promotion and sales, as well as the R&D, production and distribution of maternal, infant and nutritional supplements.

Per Frost & Sullivan industry data based on 2024 revenue, the Company ranks among the top ten players in China’s pharmaceutical marketing, promotion and sales market, and holds the leading position as China’s largest service provider specialised in paediatric pharmaceutical marketing, promotion and sales, with around 15.9% market share nationwide.

The Company’s sales network covers all 31 provincial-level regions across Chinese Mainland. As at 30 June 2025, it operated a distribution network of over 1,500 distributors, covering roughly 110,000 clinics, 310,000 pharmacies and 3,600 hospitals. Its pharmaceutical marketing, promotion and sales segment is anchored by two flagship paediatric prescription drugs, Medilac-Vita (Mamiai) and Ambrocol (Yitanjing), for which the Group serves as the exclusive distributor in China’s off-hospital niche market.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

COREE IPO IPO application lapsed